Login to Your Account



Clinic roundup


Monday, April 28, 2014
Xeris Pharmaceuticals Inc., of Austin, Texas, said it dosed the first subject in a phase II study of its stable liquid glucagon in an Insulet Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription